Few areas excite Nicole Junkermann more than the point where medicine meets modern technology. Healthtech promises better outcomes for patients and a more sustainable path for health systems, and the United Kingdom is well placed to lead. Nicole Junkermann has supported companies working on exactly these questions, and she sees Britain's combination of science, data and clinical excellence as a genuine strength.
The United Kingdom has a rare set of ingredients. World class universities, a long tradition in the life sciences, and a health service that treats millions of people every year. Handled thoughtfully and with care for privacy, that depth of knowledge can help researchers understand disease and design better treatments. Nicole Junkermann has often pointed to this as one of the country's most valuable assets.
From research to real outcomes
Nicole Junkermann served on the board of Owkin, a company that applies artificial intelligence to medical research, and that work shaped her view of what good healthtech looks like. The goal is not technology for its own sake. It is faster, more precise research, and treatments that reach patients sooner. British institutions, she believes, are natural partners for that mission.
Her interest in the field is also personal and philanthropic. Nicole Junkermann has supported the Royal Marsden Cancer Charity, one of the United Kingdom's leading centres for cancer treatment and research, and she has long championed the idea that scientific progress and compassionate care belong together.
The role of policy and advice
Nicole Junkermann has contributed to the United Kingdom's HealthTech Advisory Board, which brought together people from technology, medicine and public life to consider how the health service might use new tools well. That experience reinforced a lesson she returns to often. Technology in healthcare succeeds when it is introduced carefully, tested rigorously, and built around the needs of patients and clinicians.
What builders should focus on
For founders working in British healthtech, Nicole Junkermann offers a consistent message. Understand the science, respect the clinical setting, and be patient. The companies that endure are the ones that earn trust, that publish their evidence, and that treat safety as a first principle rather than an afterthought.
The opportunity is large and the timing is good. With careful stewardship, Nicole Junkermann believes the United Kingdom can be one of the places where the next generation of healthtech is invented, tested and brought to the world.
Read more about Nicole Junkermann, see the full biography of Nicole Junkermann, or return to the journal.
